Table 1.
Clinical Characteristics
| Characteristics | All Patients (N = 219) | SARS-CoV-2–Positive Patients (n = 8) | P Value |
|---|---|---|---|
| Sex, female, n (%) | 89 (40.6%) | ns | |
| Age, years (median, range) | 56.9 (18.1-78.2) | 56.7 (25.5-69.5) | ns |
| >65 years | 44 (20.8%) | 2 (25.0%) | ns |
| Interval from LT, years | 6.4 (0.1-30.0) | 6.5 (0.2-15.0) | ns |
| Indication for LT | |||
| Alcohol | 42 (19.2%) | 0 (0.0%) | ns |
| Hepatitis B | 9 (4.1%) | 1 (12.5%) | ns |
| Hepatitis C | 10 (4.6%) | 0 (0.0%) | ns |
| HCC | 43 (19.6%) | 2 (25.0%) | ns |
| PSC | 26 (11.9%) | 0 (0.0%) | ns |
| Others | 79 (36%) | 5 (62.5%) | ns |
| Comorbidities | |||
| BMI, kg/m2 (mean, SD) | 25.6 (15.8-46.0) | 22.9 (20.0-32.2) | ns |
| <25 | 97 (44.3%) | 5 (62.5%) | |
| 25-30 | 74 (33.8%) | 1 (12.5%) | |
| >30 | 48 (21.9%) | 2 (25%) | |
| Cardiovascular disease | 31 (14.2%) | 1 (12.5%) | ns |
| Respiratory disease | 21 (9.6%) | 0 (0.0%) | ns |
| Hypertension | 108 (49.3%) | 5 (62.5%) | ns |
| Diabetes | 66 (30.1%) | 2 (25.0%) | ns |
| Active cancer | 3 (1.4%) | 0 (0.0%) | ns |
| Active smoking | 19 (8.7%) | 0 (0.0%) | ns |
| Leukopenia | 50 (22.8%) | 2 (25%) | ns |
| RAAS inhibitor use | 56 (25.6%) | 1 (12.5) | ns |
| Renal insufficiency | |||
| Dialysis | 11 (5.0%) | 2 (25%) | .02 |
| GFR <30 mL/min | 17 (7.7%) | 2 (25%) | |
| GFR 30-60 mL/min | 43 (19.6%) | 2 (25%) | |
| GFR <60 mL/min | 159 (72.6%) | 4 (50%) | |
| Immunosuppression | |||
| Tacrolimus | 140 (63.9%) | 5 (62.5%) | ns |
| Cyclosporine | 42 (19.2%) | 2 (25%) | ns |
| mTOR inhibitor | 54 (24.7%) | 2 (25%) | ns |
| MMF/MPA | 97 (44.3%) | 4 (50%) | ns |
Abbreviations: BMI, body mass index; GFR, glomerular filtration rate; HCC, hepatocellular carcinoma; LT, liver transplant; MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; PSC, primary sclerosing cholangitis; RAAS, renin-angiotensin-aldosterone system; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.